HCV and HCV-HIV Coinfection Cohort Study

Patients with active HCV monoinfection or HCV-HIV coinfection demonstrated by positive serology and viral RNA plasma levels were enrolled in the study when starting DAA therapy. Patients were Caucasians, older than 18 years and were recruited from three third level hospitals of Northwest Spain. A number of demographic, epidemiological, laboratory and clinical data were obtained from the patients and from their electronic medical charts. All HCV-HIV-coinfected patients were receiving ART at the inclusion time. The DAA regimens used included NS5B inhibitors (sofosbuvir, dasabuvir), NS3/4A inhibitors (glecaprevir, paritaprevir, asunaprevir, grazoprevir, simeprevir) and NS5A inhibitors (velpatasvir, ledipasvir, daclatasvir, pibrentasvir, ombistavir, elbasvir) with or without ribavirin. DAA were selected according to the attending clinician criteria. LF was assessed by TE (Fibroscan) and by the noninvasive biochemical biomarkers APRI, Forns and FIB-4 at baseline and at the 1st, 3rd, 6th, 12th and 24th months.